Trial Profile
Efficacy and safety of 40 mg, 80 mg and 160 mg KUC 7483 BS administered twice daily and 160 mg administered once a day over 8 weeks in patients with overactive bladder syndrome (a double-blind, placebo-controlled, parallel groups, dose-ranging study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2020
Price :
$35
*
At a glance
- Drugs Ritobegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 09 Oct 2020 Status changed from recruiting to completed.
- 17 Jul 2012 New trial record